REYON PHARMACEUTICAL (102460) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, REYON PHARMACEUTICAL (102460) reported revenue of 145.9 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
2025145.9 billion KRW-30.3 billion KRW-29.6 billion KRW[source]
2024148.3 billion KRW79 million KRW4.2 billion KRW[source]
2023151.1 billion KRW4.0 billion KRW3.6 billion KRW[source]
2022154.0 billion KRW9.6 billion KRW7.4 billion KRW[source]
2021142.8 billion KRW3.7 billion KRW5.5 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025467.3 billion KRW244.0 billion KRW223.3 billion KRW[source]
2024505.8 billion KRW249.7 billion KRW256.1 billion KRW[source]
2023495.1 billion KRW247.5 billion KRW247.6 billion KRW[source]
2022480.0 billion KRW232.7 billion KRW247.3 billion KRW[source]
2021475.0 billion KRW230.2 billion KRW244.9 billion KRW[source]

Cash Flow

YearOperatingInvestingFinancingSource
20251.5 billion KRW-7.3 billion KRW2.4 billion KRW[source]
2024———[source]
2023———[source]
2022———[source]
2021———[source]

Cash flow figures for the relevant year were not collected.

Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-30 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice